The aims of severe perioperative bleeding management are three-fold. First, preoperative
identification by anamesis and laboratory testing of those patients for whom the …

Patients with chronic or acute liver failure frequently show profound abnormalities in their
hemostatic system. Whereas routine laboratory tests of hemostasis suggest these …

Background The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat
life-threatening bleeding has been associated with a perceived increased risk of …

The most common medical cause of major blood loss is surgery, particularly cardiovascular
procedures, liver transplantation and hepatic resection, and major orthopedic procedures …

Background Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia
and inhibitory allo‐antibodies. It is also increasingly being used for off‐license indications to …

Background Postresection liver failure (PLF) is the major cause of death following liver
resection. However, there is no unified definition, the pathophysiology is understood poorly …

Clotting factor transfusions are vital for people with diseases such as haemophilia. In the
1970s and 1980s, transfusions with pooled plasma led to a devastatingly high number of …

Patients undergoing orthotopic liver transplantation (OLT) have excessive blood loss during
surgery that requires blood transfusions, leading to increased postoperative morbidity and …

Introduction Our aim was to develop consensus guidelines for use of recombinant activated
factor VII (rFVIIa) in massive hemorrhage. Methods A guidelines committee derived the …

Orthotopic liver transplantation (OLT) can be associated with excessive blood loss. As a
result, there may be increased risk of adverse outcomes. Activated recombinant factor VII …